Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Analytical and characterisation instruments / Sequencing and single-cell spatial characterisation platforms

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Sequencing and single-cell spatial characterisation platforms

Sequencing, imaging and single-cell analysis platforms bought by pharmaceutical and biotechnology companies, contract research organisations and academic research institutions to characterise genomes, transcriptomes, cell states and tissue architecture for target discovery, mechanism-of-action studies, biomarker development and translational research. Excludes instruments bought primarily for regulated manufacturing quality control or clinical diagnostic reporting.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
80 /100
for B2B sellers
Evidence
not sized
1 source · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Genomics, translational medicine and cell biology teams in pharmaceutical and biotechnology companies; genomics and single-cell service lines in contract research organisations; genomics and imaging research groups in academic research institutions
Buying centre
Genomics or translational research leadership, supported by laboratory directors, bioinformatics, data science and procurement; academic purchases are typically decided by principal investigators with committee or grant-office approval
Buying triggers
  • Launch or expansion of a genomics, single-cell or spatial biology programme
  • Need to resolve target mechanism, patient segment or biomarker hypothesis
  • Access and throughput limits of an existing sequencing core become a programme bottleneck
  • Replacement of an ageing sequencer, cytometer or imaging platform
Pains
  • Large instrument and facility costs, with specialist operating and bioinformatic talent requirements
  • Data generation outpaces storage, compute and bioinformatics capacity
  • Batch effects and platform differences complicate cross-study comparison
  • Instrument utilisation is difficult to optimise when workflows are shared across projects
Scores (1–5)
Pain intensity4
Purchasing power3
Reachability4
Growth5

How this was sized

Not sized yet

No source provides a revenue pool for this buyer-defined niche. Indicative arithmetic only: global life science tools revenue of USD 184.3 billion in 2025 [1] multiplied by an assumed 15% share for sequencing platforms and the sequencing-related consumables needed to run them gives USD 27.65 billion, then by an assumed 35% share for the specified buyers gives USD 9.68 billion (27.65 x 0.35). Bottom-up, Low confidence: the consumables share is an assumption, the 15% allocation is not verified, and the tools-market source is broader than the specified analytical and characterisation instrument scope.

Sources

Alongside it in Analytical and characterisation instruments

// Sell into Sequencing and single-cell spatial characterisation platforms

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.